C07K 16/2809
Against the t-cell receptor -cd3 complex
Official title: {against the T-cell receptor (TcR)-CD3 complex}
C07K16/2809 (Against the t-cell receptor -cd3 complex) appears on 1,912 US grants and 4,364 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,912
- Published applications
- 4,364
- Assignees
- 1,140
- Inventors
- 6,737
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 5 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 13 | 0 |
| 1999 | 18 | 0 |
| 2000 | 16 | 0 |
| 2001 | 11 | 5 |
| 2002 | 13 | 22 |
| 2003 | 10 | 31 |
| 2004 | 11 | 30 |
| 2005 | 8 | 44 |
| 2006 | 8 | 35 |
| 2007 | 13 | 35 |
| 2008 | 6 | 24 |
| 2009 | 14 | 22 |
| 2010 | 15 | 42 |
| 2011 | 16 | 31 |
| 2012 | 27 | 35 |
| 2013 | 18 | 66 |
| 2014 | 26 | 96 |
| 2015 | 35 | 85 |
| 2016 | 44 | 124 |
| 2017 | 64 | 191 |
| 2018 | 89 | 217 |
| 2019 | 91 | 257 |
| 2020 | 152 | 316 |
| 2021 | 158 | 355 |
| 2022 | 175 | 455 |
| 2023 | 196 | 491 |
| 2024 | 220 | 506 |
| 2025 | 234 | 466 |
| 2026 | 173 | 383 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Fusion protein comprising anti-CD3 single domain antibody, exosomal protein CD63 and RNA binding protein, and uses thereof6 Oct 2026US 12,753,232 B1China Medical University Hospital
- Methods and antibody compositions for tumor treatment29 Sep 2026US 12,747,300 B2Regeneron Pharmaceuticals, Inc.
- RNA encoding an antibody29 Sep 2026US 12,747,451 B2Cure Vac SE
- CLDN18.2/CD3 bispecific antibodies for the therapy of CLDN18.2-expressing solid tumors22 Sep 2026US 12,742,008 B2Shandong Boan Biotechnology Co., Ltd.
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Cd3 binding molecules8 Oct 2026US 2026/0308254 A1Merus N.V.
- Multispecific antibodies targeting cd3 and cd228 Oct 2026US 2026/0308255 A1
- Il-5raxcd3e t cell engaging bispecific antibody and uses thereof8 Oct 2026US 2026/0308264 A1Ajou University Industry-Academic Cooperation Foundation
- Immunotherapeutic proteins8 Oct 2026US 2026/0308271 A1Macfarlane Burnet Institute for Medical Research and Public Health Limited
Most cited
By later US patents
- Immunoglobulin variants1,380US 5,821,337 AGenentech, Inc. · 1998
- Humanised antibodies1,093US 5,859,205 ACelltech Limited · 1999
- Humanized antibodies and methods for making them1,003US 6,054,297 AGenentech, Inc. · 2000
- Method for making humanized antibodies943US 6,407,213 B1Genentech, Inc. · 2002
- Method for making heteromultimeric polypeptides932US 5,731,168 AGenentech, Inc. · 1998